Article
Cost Effectiveness of Exclusionary EGFR Testing for Taiwanese Patients Newly Diagnosed with Advanced Lung Adenocarcinoma.
PharmacoEconomics - 1 Apr 2025
Ou Huang-Tz, Tsai Jui-Hung, Chen Yi-Lin, Wu Tzu-I, Chen Li-Jun, Yang Szu-Chun
Abstract excerpt
BACKGROUND AND OBJECTIVE: Approximately half of lung adenocarcinomas in East Asia harbor epidermal growth factor receptor (EGFR) mutations. EGFR testing followed by tissue-based next-generation sequencing (NGS), upfront tissue-based NGS, and complementary NGS approaches have emerged on the front line to guide personalized therapy. We study the cost effectiveness of exclusionary EGFR testing for Taiwanese patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.